Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Completed 3Terminated 1Recruiting 1

Sponsor Class

OTHER 3NIH 1NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 36CNS 5Thoracic 3Gynecologic 3Gastrointestinal 3Sarcoma 2Other hematologic neoplasm 2Lymphoid 2Genitourinary 2Breast 2Myeloid 1

Conditions

Melanoma 5Brain Neoplasms 5Neuroblastoma 3Seminoma 2Meningioma 2Lymphoma, Non-Hodgkin 2Hodgkin Disease 2Glioblastoma 2Xeroderma Pigmentosum 1Vulvar Neoplasms 1Uveal Melanoma 1Turcot syndrome 1Thyroid Neoplasms 1Testicular Neoplasms 1Teratoma, Testicular 1Teratoma 1Somatostatinoma 1Rhabdomyosarcoma 1Rare Diseases 1Pseudomyxoma Peritonei 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1Perivascular Epithelioid Cell Neoplasms 1Parathyroid Neoplasms 1Paranasal Sinus Neoplasms 1Paraganglioma 1Paget Disease, Extramammary 1Osteosarcoma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1

Interventions

Radiosurgery 22Nivolumab 21Ipilimumab 19pembrolizumab 15Temozolomide 11dabrafenib 10binimetinib 10encorafenib 8Cyclophosphamide 8trametinib 7Magnetic Resonance Spectroscopy 7Bevacizumab 6fludarabine 5cobimetinib 5Specimen Handling 5CTLA-4 Antigen 5fludarabine phosphate 3aldesleukin 3Vemurafenib 3Thalidomide 3Paclitaxel 3Oxaliplatin 3Interleukin-2 3Gemcitabine 3Drug Therapy 3Carboplatin 3130-nm albumin-bound paclitaxel 3ulixertinib 2tovorafenib 2relatlimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Melanoma × CTLA-4 Antigen × CNS × Clear all
NCT05341349 2026-04-23

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases

Emory University

Phase 1 Terminated
1 enrolled
CNSDermatologic

Uveal Melanoma, Brain Neoplasms, Melanoma

NCT03873818 2026-01-09

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

M.D. Anderson Cancer Center

Phase 2 Completed
24 enrolled 13 charts
CNSDermatologic

Brain Neoplasms, Melanoma

NCT04511013 2025-09-11

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

SWOG Cancer Research Network

Phase 2 Recruiting
112 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

NCT02107755 2024-05-21

Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma

Ohio State University Comprehensive Cancer Center

Phase 2 Completed
8 enrolled 12 charts
CNSDermatologic

Brain Neoplasms, Melanoma

NCT02304458 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

National Cancer Institute (NCI)

Phase 1/2 Completed
140 enrolled 23 charts
CNSDermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Non-Hodgkin, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡